Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company focused on developing engineered therapies targeting cytokine pathways, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. CEO Caroline Loew, Ph.D., will deliver a presentation on March 4, 2025, at 3:10 p.m. ET.
The presentation will be accessible via live webcast through the company's investor relations website at ir.muraloncology.com/events-and-presentations. For those unable to attend the live session, a recorded version will be made available for later viewing on the same platform.
Mural Oncology (Nasdaq: MURA), un'azienda di immuno-oncologia in fase clinica focalizzata sullo sviluppo di terapie ingegnerizzate che mirano ai percorsi delle citochine, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute TD Cowen. Il CEO Caroline Loew, Ph.D., presenterà il 4 marzo 2025, alle 15:10 ET.
La presentazione sarà accessibile tramite webcast dal vivo attraverso il sito web delle relazioni con gli investitori dell'azienda all'indirizzo ir.muraloncology.com/events-and-presentations. Per coloro che non possono partecipare alla sessione dal vivo, una versione registrata sarà resa disponibile per la visione successiva sulla stessa piattaforma.
Mural Oncology (Nasdaq: MURA), una empresa de inmuno-oncología en etapa clínica centrada en el desarrollo de terapias diseñadas que apuntan a las vías de citoquinas, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud TD Cowen. La CEO Caroline Loew, Ph.D., dará una presentación el 4 de marzo de 2025, a las 3:10 p.m. ET.
La presentación estará disponible a través de una transmisión en vivo en el sitio web de relaciones con inversores de la empresa en ir.muraloncology.com/events-and-presentations. Para aquellos que no puedan asistir a la sesión en vivo, se hará disponible una versión grabada para su visualización posterior en la misma plataforma.
뮤럴 온콜로지 (Nasdaq: MURA)는 사이토카인 경로를 겨냥한 엔지니어링 치료제 개발에 집중하는 임상 단계의 면역 종양학 회사로, TD 코웬 제45회 연례 건강 관리 회의에 참여할 예정이라고 발표했습니다. CEO 캐롤라인 로우, Ph.D.는 2025년 3월 4일 오후 3시 10분 ET에 발표를 진행할 것입니다.
발표는 회사의 투자자 관계 웹사이트인 ir.muraloncology.com/events-and-presentations를 통해 실시간 웹캐스트로 접근할 수 있습니다. 실시간 세션에 참석할 수 없는 분들을 위해, 같은 플랫폼에서 나중에 볼 수 있는 녹화된 버전이 제공될 예정입니다.
Mural Oncology (Nasdaq: MURA), une entreprise d'immuno-oncologie en phase clinique axée sur le développement de thérapies ingénierées ciblant les voies des cytokines, a annoncé sa prochaine participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. La PDG Caroline Loew, Ph.D., fera une présentation le 4 mars 2025 à 15h10 ET.
La présentation sera accessible par webdiffusion en direct via le site web des relations investisseurs de l'entreprise à l'adresse ir.muraloncology.com/events-and-presentations. Pour ceux qui ne peuvent pas assister à la session en direct, une version enregistrée sera disponible ultérieurement sur la même plateforme.
Mural Oncology (Nasdaq: MURA), ein Unternehmen für Immunonkologie in der klinischen Phase, das sich auf die Entwicklung von ingenieurtechnisch gestalteten Therapien zur Zielrichtung von Zytokinwegen konzentriert, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. CEO Caroline Loew, Ph.D., wird am 4. März 2025 um 15:10 Uhr ET eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast über die Investor-Relations-Website des Unternehmens unter ir.muraloncology.com/events-and-presentations zugänglich sein. Für diejenigen, die an der Live-Sitzung nicht teilnehmen können, wird eine aufgezeichnete Version später auf derselben Plattform verfügbar sein.
- None.
- None.
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at https://ir.muraloncology.com/events-and-presentations. A replay of the webcast will be archived and available following the event.
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. Our lead candidate, nemvaleukin alfa, is currently in potentially registrational trials in platinum-resistant ovarian cancer and mucosal melanoma reading out in late Q1/early Q2 and Q2 of 2025, respectively. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Contact:
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
When is Mural Oncology (MURA) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Mural Oncology's (MURA) TD Cowen conference presentation?
What type of therapies is Mural Oncology (MURA) developing?
Who will represent Mural Oncology (MURA) at the TD Cowen Healthcare Conference 2025?
